Here are three things to know:
1. Mr. Schorer has nearly two decades of executive experience in the medical device industry.
2. He most recently served as a consultant to numerous boards and CEOs in the medical device, biologics and related markets, before which he was president of the Americas at Johnson & Johnson.
3. He also co-founded and was CEO of CentriMed, and founded and led IST: Innovative Spinal Technologies.
“I know that the company has experienced issues recently, and I intend to develop a path forward that will help EndoBarrier achieve its full potential as a potentially life-changing solution for patients with type 2 diabetes,” said Mr. Schorer. “I have been impressed by the positive data generated through GI Dynamics’ multiple clinical studies and thousands of patients receiving EndoBarrier Therapy, as well as the vocal advocacy of the clinicians who have implanted EndoBarrier.”
More articles on GI/endoscopy:
Stay ahead of the quality-reporting game: Leverage data to maximize outcomes & reimbursement
Boston Scientific launches AXIOS Stent, EndoGastric Solutions presents promising 3-year TIF data — 6 GI company key notes
El Camino Hospital launches 1st GutCheck System trial: 4 points
